CAMBRIDGE, MA and ROCKVILLE, MD, USA I April 28, 2025 I Clasp Therapeutics, a biotechnology company bringing unparalleled precision to immuno-oncology with ...

In the study, patients with advanced solid tumors must be HLA-A*02:01 positive and harbor a p53 R175H mutation.

More information: Zhigang Nian et al, Interleukin-34-orchestrated tumor-associated macrophage reprogramming is required for ...

The poster will be available on SELLAS websites following the session.

The groups interested in studying p53 next wanted to investigate its interactions with T antigen. Scientists made these findings as the theory of oncogenes, the idea that mutated host growth-promoting ...

Sponsored by the biology department and the Michael J. Wolk Foundation, Alea Mills, a professor at Cold Spring Harbor ...